2024 Q2 Form 10-Q Financial Statement
#000167479624000019 Filed on August 26, 2024
Income Statement
| Concept | 2024 Q2 |
|---|---|
| Revenue | $0.00 |
| YoY Change | |
| Cost Of Revenue | |
| YoY Change | |
| Gross Profit | |
| YoY Change | |
| Gross Profit Margin | |
| Selling, General & Admin | $16.56K |
| YoY Change | -49.8% |
| % of Gross Profit | |
| Research & Development | |
| YoY Change | |
| % of Gross Profit | |
| Depreciation & Amortization | |
| YoY Change | |
| % of Gross Profit | |
| Operating Expenses | $16.56K |
| YoY Change | -49.82% |
| Operating Profit | -$16.56K |
| YoY Change | -49.82% |
| Interest Expense | $84.00 |
| YoY Change | -93.56% |
| % of Operating Profit | |
| Other Income/Expense, Net | -$84.00 |
| YoY Change | -93.56% |
| Pretax Income | -$16.64K |
| YoY Change | -51.48% |
| Income Tax | $0.00 |
| % Of Pretax Income | |
| Net Earnings | -$16.64K |
| YoY Change | -51.48% |
| Net Earnings / Revenue | |
| Basic Earnings Per Share | $0.00 |
| Diluted Earnings Per Share | $0.00 |
| COMMON SHARES | |
| Basic Shares Outstanding | 5.249M shares |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2024 Q2 |
|---|---|
| SHORT-TERM ASSETS | |
| Cash & Short-Term Investments | $5.160K |
| YoY Change | 122.41% |
| Cash & Equivalents | $5.155K |
| Short-Term Investments | |
| Other Short-Term Assets | |
| YoY Change | |
| Inventory | |
| Prepaid Expenses | |
| Receivables | |
| Other Receivables | |
| Total Short-Term Assets | $5.155K |
| YoY Change | 122.2% |
| LONG-TERM ASSETS | |
| Property, Plant & Equipment | |
| YoY Change | |
| Goodwill | |
| YoY Change | |
| Intangibles | |
| YoY Change | |
| Long-Term Investments | |
| YoY Change | |
| Other Assets | |
| YoY Change | |
| Total Long-Term Assets | $0.00 |
| YoY Change | |
| TOTAL ASSETS | |
| Total Short-Term Assets | $5.155K |
| Total Long-Term Assets | $0.00 |
| Total Assets | $5.155K |
| YoY Change | 122.2% |
| SHORT-TERM LIABILITIES | |
| YoY Change | |
| Accounts Payable | $1.350K |
| YoY Change | -99.68% |
| Accrued Expenses | $80.00 |
| YoY Change | -99.22% |
| Deferred Revenue | |
| YoY Change | |
| Short-Term Debt | $21.60K |
| YoY Change | -75.8% |
| Long-Term Debt Due | |
| YoY Change | |
| Total Short-Term Liabilities | $23.03K |
| YoY Change | -95.59% |
| LONG-TERM LIABILITIES | |
| Long-Term Debt | $0.00 |
| YoY Change | |
| Other Long-Term Liabilities | |
| YoY Change | |
| Total Long-Term Liabilities | $0.00 |
| YoY Change | |
| TOTAL LIABILITIES | |
| Total Short-Term Liabilities | $23.03K |
| Total Long-Term Liabilities | $0.00 |
| Total Liabilities | $23.03K |
| YoY Change | -95.59% |
| SHAREHOLDERS EQUITY | |
| Retained Earnings | -$6.065M |
| YoY Change | 2.08% |
| Common Stock | $41.56K |
| YoY Change | 691.92% |
| Preferred Stock | |
| YoY Change | |
| Treasury Stock (at cost) | |
| YoY Change | |
| Treasury Stock Shares | |
| Shareholders Equity | -$17.88K |
| YoY Change | |
| Total Liabilities & Shareholders Equity | $5.155K |
| YoY Change | 122.2% |
Cashflow Statement
| Concept | 2024 Q2 |
|---|---|
| OPERATING ACTIVITIES | |
| Net Income | -$16.64K |
| YoY Change | -51.48% |
| Depreciation, Depletion And Amortization | |
| YoY Change | |
| Cash From Operating Activities | $18.52K |
| YoY Change | -721.48% |
| INVESTING ACTIVITIES | |
| Capital Expenditures | |
| YoY Change | |
| Acquisitions | |
| YoY Change | |
| Other Investing Activities | $0.00 |
| YoY Change | |
| Cash From Investing Activities | $0.00 |
| YoY Change | |
| FINANCING ACTIVITIES | |
| Cash Dividend Paid | |
| YoY Change | |
| Common Stock Issuance & Retirement, Net | |
| YoY Change | |
| Debt Paid & Issued, Net | |
| YoY Change | |
| Cash From Financing Activities | -14.20K |
| YoY Change | -373.6% |
| NET CHANGE | |
| Cash From Operating Activities | 18.52K |
| Cash From Investing Activities | 0.000 |
| Cash From Financing Activities | -14.20K |
| Net Change In Cash | 4.320K |
| YoY Change | 95.48% |
| FREE CASH FLOW | |
| Cash From Operating Activities | $18.52K |
| Capital Expenditures | |
| Free Cash Flow | |
| YoY Change |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q2 | ||
| dei |
Document Quarterly Report
DocumentQuarterlyReport
|
true | ||
| dei |
Document Transition Report
DocumentTransitionReport
|
false | ||
| dei |
Entity Central Index Key
EntityCentralIndexKey
|
0000797564 | ||
| dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
| dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
true | ||
| dei |
Entity Small Business
EntitySmallBusiness
|
true | ||
| dei |
Entity Ex Transition Period
EntityExTransitionPeriod
|
false | ||
| dei |
Entity Shell Company
EntityShellCompany
|
false | ||
| dei |
Amendment Flag
AmendmentFlag
|
false | ||
| dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2024 | ||
| dei |
Document Type
DocumentType
|
10-Q | ||
| dei |
Document Period End Date
DocumentPeriodEndDate
|
2024-06-30 | ||
| dei |
Entity File Number
EntityFileNumber
|
000-15303 | ||
| dei |
Entity Registrant Name
EntityRegistrantName
|
HST Global, Inc. | ||
| dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
NV | ||
| dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
73-1215433 | ||
| dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
509 Old Great Neck Road | ||
| CY2024Q1 | dei |
Entity Address Address Line2
EntityAddressAddressLine2
|
Suite 105 | |
| dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Virginia Beach | ||
| dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
VA | ||
| dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
23454 | ||
| dei |
City Area Code
CityAreaCode
|
800 | ||
| dei |
Local Phone Number
LocalPhoneNumber
|
961-4750 | ||
| dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | ||
| dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | ||
| dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | ||
| CY2024Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
41561226 | shares |
| CY2024Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
5155 | usd |
| CY2023Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
1526 | usd |
| CY2024Q2 | us-gaap |
Assets Current
AssetsCurrent
|
5155 | usd |
| CY2023Q4 | us-gaap |
Assets Current
AssetsCurrent
|
1526 | usd |
| CY2024Q2 | us-gaap |
Assets
Assets
|
5155 | usd |
| CY2023Q4 | us-gaap |
Assets
Assets
|
1526 | usd |
| CY2024Q2 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
1350 | usd |
| CY2023Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
2275 | usd |
| CY2024Q2 | fil |
Accounts Payable And Accrued Expenses Related Parties
AccountsPayableAndAccruedExpensesRelatedParties
|
0 | usd |
| CY2023Q4 | fil |
Accounts Payable And Accrued Expenses Related Parties
AccountsPayableAndAccruedExpensesRelatedParties
|
480000 | usd |
| CY2024Q2 | us-gaap |
Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
|
21600 | usd |
| CY2023Q4 | us-gaap |
Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
|
98319 | usd |
| CY2024Q2 | fil |
Accrued Related Party Interest
AccruedRelatedPartyInterest
|
84 | usd |
| CY2023Q4 | fil |
Accrued Related Party Interest
AccruedRelatedPartyInterest
|
12999 | usd |
| CY2024Q2 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
23034 | usd |
| CY2023Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
593593 | usd |
| CY2024Q2 | us-gaap |
Liabilities
Liabilities
|
23034 | usd |
| CY2023Q4 | us-gaap |
Liabilities
Liabilities
|
593593 | usd |
| CY2024Q2 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | usd |
| CY2023Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | usd |
| CY2024Q2 | us-gaap |
Common Stock Value
CommonStockValue
|
41560 | usd |
| CY2023Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
5248 | usd |
| CY2024Q2 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
6005929 | usd |
| CY2023Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
5417236 | usd |
| CY2024Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-6065368 | usd |
| CY2023Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-6014551 | usd |
| CY2024Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-17879 | usd |
| CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-592067 | usd |
| CY2024Q2 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
5155 | usd |
| CY2023Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
1526 | usd |
| CY2024Q2 | us-gaap |
Revenues
Revenues
|
0 | usd |
| CY2023Q2 | us-gaap |
Revenues
Revenues
|
0 | usd |
| us-gaap |
Revenues
Revenues
|
0 | usd | |
| us-gaap |
Revenues
Revenues
|
0 | usd | |
| CY2024Q2 | us-gaap |
Labor And Related Expense
LaborAndRelatedExpense
|
0 | usd |
| CY2023Q2 | us-gaap |
Labor And Related Expense
LaborAndRelatedExpense
|
30000 | usd |
| us-gaap |
Labor And Related Expense
LaborAndRelatedExpense
|
30000 | usd | |
| us-gaap |
Labor And Related Expense
LaborAndRelatedExpense
|
60000 | usd | |
| CY2024Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
16556 | usd |
| CY2023Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2990 | usd |
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
19244 | usd | |
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
11065 | usd | |
| CY2024Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
16556 | usd |
| CY2023Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
32990 | usd |
| us-gaap |
Operating Expenses
OperatingExpenses
|
49244 | usd | |
| us-gaap |
Operating Expenses
OperatingExpenses
|
71065 | usd | |
| CY2024Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-16556 | usd |
| CY2023Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-32990 | usd |
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-49244 | usd | |
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-71065 | usd | |
| CY2024Q2 | us-gaap |
Interest Expense
InterestExpense
|
84 | usd |
| CY2023Q2 | us-gaap |
Interest Expense
InterestExpense
|
1305 | usd |
| us-gaap |
Interest Expense
InterestExpense
|
1573 | usd | |
| us-gaap |
Interest Expense
InterestExpense
|
2516 | usd | |
| CY2024Q2 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-84 | usd |
| CY2023Q2 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-1305 | usd |
| us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-1573 | usd | |
| us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-2516 | usd | |
| CY2024Q2 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-16640 | usd |
| CY2023Q2 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-34295 | usd |
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-50817 | usd | |
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-73581 | usd | |
| CY2024Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd |
| CY2023Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd |
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd | |
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd | |
| CY2024Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-16640 | usd |
| CY2023Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-34295 | usd |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-50817 | usd | |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-73581 | usd | |
| CY2024Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0 | |
| CY2023Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.01 | |
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0 | ||
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.01 | ||
| CY2024Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
31984264 | shares |
| CY2023Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
5248582 | shares |
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
15090838 | shares | |
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
5248582 | shares | |
| us-gaap |
Profit Loss
ProfitLoss
|
-50817 | usd | |
| us-gaap |
Profit Loss
ProfitLoss
|
-73581 | usd | |
| fil |
Expenses Paid Directly By Related Party Formalized As Loc
ExpensesPaidDirectlyByRelatedPartyFormalizedAsLOC
|
5800 | usd | |
| fil |
Expenses Paid Directly By Related Party Formalized As Loc
ExpensesPaidDirectlyByRelatedPartyFormalizedAsLOC
|
0 | usd | |
| us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
29273 | usd | |
| us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
60000 | usd | |
| us-gaap |
Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
|
1573 | usd | |
| us-gaap |
Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
|
2517 | usd | |
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-14171 | usd | |
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-11064 | usd | |
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
0 | usd | |
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
0 | usd | |
| us-gaap |
Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
|
17800 | usd | |
| us-gaap |
Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
|
13194 | usd | |
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
17800 | usd | |
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
13194 | usd | |
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
3629 | usd | |
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
2130 | usd | |
| CY2023Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
1526 | usd |
| CY2022Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
190 | usd |
| CY2024Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
5155 | usd |
| CY2023Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
2320 | usd |
| us-gaap |
Interest Paid
InterestPaid
|
0 | usd | |
| us-gaap |
Interest Paid
InterestPaid
|
0 | usd | |
| us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
0 | usd | |
| us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
0 | usd | |
| us-gaap |
Nature Of Operations
NatureOfOperations
|
<p style="font:11pt Times New Roman;margin-top:0pt;margin-bottom:12pt;color:#000000"><b>NOTE 1 – ORGANIZATION AND PRINCIPAL ACTIVITIES </b></p> <p style="font:11pt Times New Roman;margin-top:0pt;margin-bottom:12pt;color:#000000;text-align:justify">HST Global, Inc. (the "Company") was incorporated on April 11, 1984 under the laws of the State of Delaware under the name of NT Holding Corporation (“NTHC”). The Company made several acquisitions and disposals of various business entities and activities. On May 9, 2008, the Company entered into a merger and share exchange agreement with Health Source Technologies, Inc. (“HSTI”) This business acquisition was accounted for as a reverse merger or recapitalization of HSTI At the time of the merger NTHC had disposed of its assets and liabilities and had minimal operations. Immediately after the acquisition the Company changed its name to HST Global, Inc. HSTI was incorporated under the laws of the State of Nevada on August 6, 2007. The Company was headquartered in Hampton, VA on March 31, 2024 and is currently headquartered in Virginia Beach, Virginia.</p> <p style="font:11pt Times New Roman;margin-top:0pt;margin-bottom:12pt;text-align:justify">The Company was founded as an integrated health and wellness biotechnology company with a plan to develop and /or acquire a network of wellness centers worldwide that would be primarily focused on the homeopathic and alternative treatment of late stage cancer. </p> <p style="font:11pt Times New Roman;margin:0;text-align:justify">The Company is a dynamic public holding company, strategically focused on the intersection of the healthcare, software, and transportation industries. With a commitment to innovation and excellence, HST Global specializes in identifying potential investment opportunities and spearheading ventures within these critical sectors.</p> <p style="font:11pt Times New Roman;margin:0"> </p> <p style="font:11pt Times New Roman;margin:0"><b><i>Core Industries</i></b></p> <p style="font:11pt Times New Roman;margin:0"> </p> <p style="font:11pt Times New Roman;margin:0;text-align:justify"><kbd style="position:absolute;font:11pt Times New Roman;margin-left:0pt">•</kbd><kbd style="margin-left:36pt"></kbd><i>Healthcare</i>: The Company seeks to invest in companies that are at the forefront of medical technology, healthcare services, and solutions that enhance patient care and improve clinical outcomes. </p> <p style="font:11pt Times New Roman;margin:0;text-align:justify"> </p> <p style="font:11pt Times New Roman;margin:0;text-align:justify"><kbd style="position:absolute;font:11pt Times New Roman;margin-left:0pt">•</kbd><kbd style="margin-left:36pt"></kbd><i>Software</i>: Recognizing the transformative power of technology, the Company seeks to fund and develop cutting-edge software solutions that drive efficiency, productivity, and growth across various industries. </p> <p style="font:11pt Times New Roman;margin:0;text-align:justify"> </p> <p style="font:11pt Times New Roman;margin:0;text-align:justify"><kbd style="position:absolute;font:11pt Times New Roman;margin-left:0pt">•</kbd><kbd style="margin-left:36pt"></kbd><i>Transportation</i>: With an eye on the future, the Company is involved in ventures that revolutionize how goods and people move, focusing on sustainable and intelligent transportation systems. </p> <p style="font:11pt Times New Roman;margin:0;text-align:justify"> </p> <p style="font:11pt Times New Roman;margin:0;text-align:justify"><b><i>Investment Philosophy</i></b></p> <p style="font:11pt Times New Roman;margin:0"> </p> <p style="font:11pt Times New Roman;margin:0">The Company's investment philosophy centers on creating value through strategic acquisitions and the nurturing of innovative ideas into successful business ventures. By leveraging its industry insight and operational expertise, the Company aims to generate sustainable earnings growth and long-term value for its shareholders.</p> <p style="font:11pt Times New Roman;margin:0"> </p> <p style="font:11pt Times New Roman;margin:0"><b><i>Vision and Mission</i></b></p> <p style="font:11pt Times New Roman;margin:0"> </p> <p style="font:11pt Times New Roman;margin:0;text-align:justify"><i>Vision</i>: To be a leading holding company known for transforming high-potential ideas into leading enterprises in healthcare, software, and transportation.</p> <p style="font:11pt Times New Roman;margin:0"> </p> <p style="font:11pt Times New Roman;margin:0"><i>Mission</i>: To invest in and develop businesses that lead their respective industries while delivering consistent returns and growth to our stakeholders.</p> <p style="font:11pt Times New Roman;margin:0"> </p> <p style="font:11pt Times New Roman;margin-top:0pt;margin-bottom:12pt;color:#000000;text-align:justify">The accompanying interim condensed financial statements have been prepared in accordance with the instructions to Form 10-Q pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and, therefore, do not include all information and footnotes necessary for a complete presentation of the Company’s financial </p> <p style="font:11pt Times New Roman;margin-top:0pt;margin-bottom:12pt;color:#000000;text-align:justify">position, results of operations, cash flows, and stockholders’ equity in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature. The unaudited quarterly condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Annual Report on Form 10-K of the Company as of and for the fiscal year ended December 31, 2023. The results of operations for the period ended June 30, 2024, are not necessarily indicative of the results for a full-year period.</p> | ||
| us-gaap |
Basis Of Accounting
BasisOfAccounting
|
<p style="font:11pt Times New Roman;margin-top:0pt;margin-bottom:12pt;color:#000000"><span style="border-bottom:1px solid #000000">Basis of Presentation</span></p> <p style="font:11pt Times New Roman;margin-top:0pt;margin-bottom:12pt;color:#000000;text-align:justify">The accompanying condensed financial statements and related notes include the activity of the Company and have been prepared in accordance with U.S. GAAP and with the rules and regulations of the SEC to Form 10-K and 10-Q. </p> | ||
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="font:11pt Times New Roman;margin-top:0pt;margin-bottom:12pt;color:#000000"><span style="border-bottom:1px solid #000000">Use of Estimates</span></p> <p style="font:11pt Times New Roman;margin-top:0pt;margin-bottom:12pt;color:#000000;text-align:justify">The preparation of condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the condensed financial statements, and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> |
